# **TAMIRNA** Our know-how for your samples

customeritailored microphy services



# The right tool for the right job

TAmiRNA offers a broad range of high quality RNA services performed by experts according to GLP standards

- RNA isolation
- Next Generation Sequencing
- RT-qPCR

"We are committed to help our clients to rapidly move from an idea to results, to facilitate the publication and clinical application of microRNA biomarkers!" Matthias Hackl, CEO TAMIRNA

### We established standardized analytical procedures for the following technologies and biological specimens:

	cells	tissue	serum / plasma	urine
Required Input	> 10 <sup>3</sup> cells	> 35 mg	50–200 μL	50–200 μL
RNA Extraction *	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Real-Time Quantitative PCR	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Next Generation Sequencing (NGS)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

\* TAmiRNA offers RNA isolation of biofluids (serum/plasma), cells and tissue, followed by quality control of total RNA using bioanalyzer chips.

### Additional options

#### Extracellular Vesicles (EVs)

purification of EVs according to official recommendations by the International Society for Extracellular Vesicles (ISEV)

#### **Liquid biopsy**

pilot studies for a variety of biofluids such as cerebral spine fluid (CSF), saliva, and tears

#### IVD test

proprietary normalization strategies and machine learning are applied to discover and validate multivariate biomarker signatures with robust diagnostic performance

## RNA service project workflow

1. Discussion of study design

# 2. Project proposal and quote

## 3. Project start

4. Sample submission

5. RNA isolation

# 6. RNA quality control

7. miRNA expression analysis

# 8. Data report and discussion

9. Project finalization

## At a glance: TA<mark>mi</mark>RNA's RNA services

• "One-for-All"

a single partner for the whole workflow from study design to project finalization, consultation and next steps

• Flexibility

adjustments of tasks and protocols according to your individual project needs and budget

- **Quality** SOPs and comprehensive QC at every step of the project
- Speed

accelerate your research – rapid turnaround times to fit your project timelines

• Results

ready-to-use data for presentations and publications as well as for additional analyses. Post project consultations to discuss next steps are included.

### • Experience

benefit from our know-how of >10 years of RNA research and IVD-test development



## From discovery to validation

#### Discovery

Genome-wide screening of hundreds to thousands of biomarker candidates (qPCR or NGS)

Identification of lead biomarker candidates – stop/go decision

#### Verification

Focussed analysis of selected biomarker candidates using custom qPCR plates or individual assays


Selection of final biomarker signature for validation – stop/go decision

#### Validation

Targeted analysis of the selected biomarker signatures to determine diagnostic performances:


Sensitivity/Specificity, Accuracy, AUC, PPV, NPV

## Exemplary results



## Step 1 | Exploratory data analysis

## Step 2 | Differential expression analysis



## Successfully published projects

Serum microRNAs are indicative of skeletal fractures in postmenopausal women with and without type-2 diabetes and influence osteogenic and adipogenic differentiation of adipose-tissue derived mesenchymal stem cells in vitro. Heilmeier U, et al. 2016 J Bone Miner Res. 2173-2192. PMID: 27345526

Original research article on discovery of novel microRNA biomarkers for the mangement of postmenopausal and diabetic osteoporosis.

Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures. Kocijan R, et al. 2016 J Clin Endocrinol Metab. 2016-2365. PubMed PMID: 27552543 Original research article on microRNAs and tissue homeostasis.

Vesicular Galectin-3 levels decrease with donor age and contribute to the reduced osteo-inductive potential of human plasma derived extracellular vesicles. Weilner S, et al. 2016 Aging, Jan 9. PMID: 26752347

Original research article investigating the donor-age dependent impact of extracellular vesicles on osteogenesis in vitro.

Urine is a novel source of autologous mesenchymal stem cells for patients with epidermolysis bullosa. Schosserer M, et al. 2015 BMC Res Notes, 10;8(1):767. PMID: 26654529

Original research article on urine derived mesenchymal stem cells and their capability to differentiate into osteoblasts, adipocytes and keratinocytes. **Circulating microRNAs as novel biomarkers for bone diseases – Complex signatures for multifactorial diseases?** Hackl M, et al. 2015 Mol Cell Endocrinol. 23. pii. S0303-7207(15)30116-7.

PMID: 26525415

Review on microRNAs and their usability as biomarkers for bone diseases

Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. Weilner S, et al. 2015 Bone. 28;79:43-51. PMID: 26026730

Original research article which reports the identification of circulating microRNAs that are changed in the course of recent osteoporotic fractures in postmenopausal women, and which show osteogenic activity in vitro.

Annotation of additional evolutionary conserved microRNAs in CHO cells from updated genomic data. Diendorfer AB, et al. 2015 Biotechnol Bioeng. 112(7):1488-93. PMID: 25689160

Orginial research article describing the expansion of the Chinese hamster ovary cell miRNome through massive-parallel sequencing and microarray analysis.

Molecular and cellular effects of in vitro shockwave treatment on lymphatic endothelial cells. Rohringer S, et al. 2014 PLoS One. 11;9(12).

PMID: 25502694.

Original research article on investigating in vitro shockwave treatment (IVSWT) effects on lymphatic endothelial cell (LEC) behavior and lymphangiogenesis.

MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. Reynoso R, et al. 2014 Scientific Reports. 1;4:5915. PMID: 25081906.

Original research article on circulating microRNAs in chronic HIV-infected patients and elite control patients, and their potential use as therapeutic targets. Identification of microRNAs specific for high producer CHO cell lines using steadystate cultivation. Maccani A, et al. 2014 Appl Microbiol Biotechnol. 98(17):7535-48. PMID: 25052466

Original research article reporting microarray data of microRNA and mRNA transcription in low and high producing CHO cell lines during a continuous pilotscale fermentation process.

Stable overexpression of miR-17 enhances recombinant protein production of CHO cells. Jadhav V, et al. 2014 J Biotechnol. 175:38-44. PMID: 24518263

Original research article reporting the positive effect of an oncogenic microR-NA – miR-17 – on recombinant protein expression in CHO cell lines.

Analysis of microRNA transcription and post-transcriptional processing by Dicer in the context of CHO cell proliferation. Hackl M, et al. 2014 J Biotechnol. pii:S0168-1656(14)00037-6. PMID: 24486028.

Original research article reporting the importance of post-transcriptional processing of microRNAs by DICER for CHO cell proliferation.

Endogenous microRNA clusters outperform chimeric sequence clusters in Chinese hamster ovary cells. Klanert G, et al. 2014 Biotechnol J. 9(4):538-44. PMID: 24323929.

Orginal research article reporting strategies for improved microRNA overexpression in CHO cell lines for cell engineering purposes.



TA<mark>mi</mark>RNA GmbH Muthgasse 18 1190 Vienna, Austria

+43 660 420 58 56 office@tamirna.com www.tamirna.com

exclusively distributed by



Biomedica Medizinprodukte GmbH & Co KG Divischgasse 4 1210 Vienna, Austria

+43 1 291 07 45 export@bmgrp.com www.bmgrp.com